BRIEF—PharmaMar closes recruitment for the Phase III Neptuno trial

Spanish drugmaker PharmaMar has announced it is closing the Phase III Neptuno trial with plitidepsin for the treatment of COVID-19 in hospitalized patients.

The company has made this decision due to the lack of enrollment of patients for the study given the evolution of the pandemic.

Despite an insufficient sample of patients, a preliminary analysis suggests a positive trend, demonstrating the drug's potent activity.

PharmaMar will continue to analyze the trial data for a subsequent publication.

Ahead of the Neptuno study, PharmaMar announced the final results of its APLICOV-PC trial with Aplidin (plitidepsin) for the treatment of adults with COVID-19 requiring hospitalization, which met the primary safety endpoint and showed clinical efficacy.